Difference between revisions of "PARP inhibitors"
Jump to navigation
Jump to search
(create) |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
''PARP'' is an abbreviation for ''poly-ADP ribose polymerase''. | ''PARP'' is an abbreviation for ''poly-ADP ribose polymerase''. | ||
==Use== | |||
*Prostate cancer. | |||
*Breast cancer. | |||
*Ovarian cancer. | |||
==Drugs== | ==Drugs== | ||
*Olaparib (Lynparza).<ref name=pmid28250726>{{cite journal |authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A |title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting |journal=Prz Menopauzalny |volume=15 |issue=4 |pages=215–219 |date=December 2016 |pmid=28250726 |pmc=5327624 |doi=10.5114/pm.2016.65667 |url=}}</ref> | *Olaparib (Lynparza).<ref name=pmid28250726>{{cite journal |authors=Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A |title=PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting |journal=Prz Menopauzalny |volume=15 |issue=4 |pages=215–219 |date=December 2016 |pmid=28250726 |pmc=5327624 |doi=10.5114/pm.2016.65667 |url=}}</ref> | ||
*Rucaparib (Rubraca). | *Rucaparib (Rubraca). | ||
*Niraparib (Zejula). | *Niraparib (Zejula).<ref>URL: [https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs/types/PARP-inhibitors https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs/types/PARP-inhibitors]. Accessed on: 2024 June 10.</ref> | ||
==See also== | ==See also== | ||
*[[Hereditary breast cancer]] | *[[Hereditary breast cancer]]. | ||
*[[Ovarian tumours]]. | |||
==References== | ==References== | ||
Latest revision as of 18:28, 10 June 2024
PARP inhibitors are a class of cancer drugs.
PARP is an abbreviation for poly-ADP ribose polymerase.
Use
- Prostate cancer.
- Breast cancer.
- Ovarian cancer.
Drugs
See also
References
- ↑ Dziadkowiec KN, Gąsiorowska E, Nowak-Markwitz E, Jankowska A (December 2016). "PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting". Prz Menopauzalny 15 (4): 215–219. doi:10.5114/pm.2016.65667. PMC 5327624. PMID 28250726. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327624/.
- ↑ URL: https://www.cancerresearchuk.org/about-cancer/treatment/targeted-cancer-drugs/types/PARP-inhibitors. Accessed on: 2024 June 10.